Even with extensive treatment, many patients with type 2 diabetes mellitus (T2DM) have poorly managed illness. The goal of this open-label, prospective, non-randomized, single-centric observational trial was to determine the efficacy and safety of pioglitazone in conjunction with other antidiabetics (ADs) in Indian T2DM patients.
Clinical evaluation, medication history, physical examination, and lab chemistry were used to screen all patients according to procedure. Patients who had signs of renal/hepatic decompensation, a positive pregnancy test, failure to follow the study regimen, or serious concomitant conditions were eliminated from the trial.
There are no randomised, controlled trials that directly compare pioglitazone to any other antidiabetic medication in the literature (including other thiazolidinediones). Every therapy visit resulted in a considerable improvement in glycemic indices.
From baseline to 2 years of treatment, there was no significant change in urine pH or the presence of pus and protein. Furthermore, a higher proportion of patients had no major abnormalities in urine during the entire therapy time.
The current study concludes that adding pioglitazone to existing OAD medication is an effective and well-tolerated therapeutic option for improving glycemic control in type 2 diabetic patients. It was discovered to be safe and well tolerated across the age groups examined, as well as when combined with other Ads.
